Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

"Overall, metabolic responses to glucagon stimulation in individuals with type 1 diabetes are comparable to those in healthy ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...